EPKINLY (icarelatumumab) News Flash: New Cancer Treatment Options Added

China Beijing time2025year3month21 Friday, exciting news came from the field of cancer treatment. EPKINLY (icarelatumumab), an innovative CD3/CD20 bispecific antibody drug, has been officially approved for marketing, providing a new treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).

EPKINLY (icarelatumumab) is jointly developed by AbbVie and Genmab and is constructed using Genmab’s proprietary DuoBody technology. This technology allowsEPKINLY to simultaneously interact with the CD3 receptors and B< on T cells. The binding of CD20 antigen on span>cell lymphoma cells accurately guides T cells to attack and eliminate CD20 positive lymphoma cells.

In clinical trials, EPKINLY demonstrated excellent efficacy. For patients with relapsed or refractory DLBCL, EPKINLY’s overall response rate (ORR) is as high as 61%, The complete response rate (CR) also reached 38%, and the median duration of response (DoR) was as long as 15.6 months. For patients with follicular lymphoma, EPKINLY also performed well, with ORR as high as 83%, CR is 63%, and the median DoR has reached21.4 months. These data strongly demonstrate the effectiveness and durability of EPKINLY in treating these refractory lymphomas.

In addition to its remarkable efficacy,EPKINLY also uses subcutaneous injection, which is simpler and faster than traditional intravenous injection, effectively reducing the pain and inconvenience of patients. At the same time, the safety of EPKINLY has also been fully verified, and no serious adverse reactions or side effects have been found, providing patients with a safer treatment option.

The approval of EPKINLY not only brings new treatment hope to lymphoma patients, but also further promotes the development of the field of cancer treatment. In the future, with the development and application of more innovative drugs, we have reason to believe that cancer will no longer be an incurable disease, and more patients will be able to enjoy the benefits of technology.

References:https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-epcoritamab-bysp-relapsed-or-refractory-follicular-lymphoma